成片一卡三卡四卡免费网站,色婷婷五月天,一日本道伊人久久综合影,XXXX张怕芝XXXXXBBBBB

English

ENDPOINTSNEWS: On a quest to challenge Novo Nordisk in obesity, transpacific startup picks up $70M — and a pair of seasoned execs

2021-10-13

新聞截圖.png

— AUTHOR: Amber Tong, Senior Editor

— REPRINTED FROM ENDPOINTSNEWS

— ORIGINAL LINK: https://endpts.com/on-a-quest-to-challenge-novo-nordisk-in-obesity-transpacific-startup-picks-up-70m-and-a-pair-of-seasoned-execs/

Four years after starting Terns Pharmaceuticals together in search of an elusive NASH win, Weidong Zhong and Martijn Fenaux are reuniting at a new startup.

On paper, Sciwind Biosciences — which just raised $70 million in Series C cash — employs a similar setup as Terns: Both have embraced the transpacific model, taking root in China but planting flags in the US.

Zhong was tapped to be president of the San Francisco-based subsidiary back in July, on top of assuming the role as chief strategy officer. Weeks later, Fenaux has been appointed SVP, nonclinical development and translational science at the parent company out of Hangzhou — joining the team alongside chief scientific officer Xinle Wu, who brings experience running R&D for both Eli Lilly and Amgen in China.

Whereas Terns is focused on NASH and other liver diseases, Sciwind positions itself as a specialist in metabolic disorders. The three lead candidates all congregate around GLP-1 receptor agonism, a mechanism that Sciwind reckons is relevant across fatty liver, obesity and diabetes.

The new infusion marks Sciwind’s second financing in a year, having bagged $37 million in February to fuel the clinical work underway for XW003 (long-acting GLP-1 peptide analog) in type 2 diabetes and obesity. Topline Phase II data are expected in the second half of 2022.

To reach those massive markets, the biotech would first have to steer past giant rivals like Novo Nordisk, whose GLP-1 peptide analog semaglutide is already approved in the US for both of those indications.

Then there's the follow-on XW004, which is designed for once daily rather than once weekly administration, slated for first-in-human trials later this year; and XW014, a preclinical small molecule GLP-1R agonist.

But IDG Capital, Loyal Valley Capital and LYFE Capital have no trouble believing in Sciwind and founder/CEO Hai Pan, leading the latest round.

无码国产精品一区二区高潮 | 国产福利姬在线观看 | 制服蜜臀17c无码 | 2019中文字幕在线电视剧免费观看 | 日本午夜精品理论片A级app发布 | 成人a片免费体验区120秒 | 精品久久BBBBB精品人妻 | 国产午夜精品A片一区仙踪林 | 乱码一区二区三区四区精品蜜桃久久 | h精品3d无码av | 国产人妻 9 9精品无码一区久久 | 波多野结衣一区二区 | 把腿扒开做爽爽的视频 | 国产亚州AP毛片一区 | 大荫蒂bbwbbb大荫道一 | 五十路六十路老熟妇A片 | 中文字幕一区二区人妻精品专区 | 亚洲AV无码永久精品 | 国产精品一区二区在线观看 | 欧美亚洲图片小说 | 蜜臀人妻四季AV一区二区 | 国产人妻人伦精品1国产丝袜 | 成人电影精品在线 | 国产一级a毛一级a看免费软件特色 | 亚洲成人AV一区二区三区 | 国产一级A毛一级A看片 | 正在播放国产精品 | 亚洲中文字幕在线观看视频 | 亚洲成人av在线 | 亚洲无码乱码精品 | 农村妇女亂伦92 | 色噜噜狠狠一区二区三区Av蜜芽 | 国产一区二区三区超碰在线观看 | 色婷婷精品久久二区二区蜜臀 | 少妇人妻偷人精品视频18禁 | 美女裸体无遮挡免费观看 | 精品国产AⅤ一区二区三区东京热 | 妇女人人插人人爽 | 黄片视频观看免费观看 | 精品传媒一区二区三区 | 辣椒资源AV在线观看 |